Researchers want to combine psilocybin and cannabis in a single medicinal treatment

The company CaaMTech first received a patent in 2021 to support research. An article published Wednesday on the Greenstate website said the company is “developing pharmaceutical drugs for mental illnesses such as depression and obsessive-compulsive disorder” and is now “exploring the therapeutic value of psilocybin in combination with cannabinoids.”

“Through their research, CaaMTech has isolated derivatives of psilocybin, cannabinoids and terpenes,” Greenstate explained.

In the 2021 patent announcement, Dr. Andrew Chadeayne, Founder and CEO of CaaMTech, that “the company’s goal from day one has been to capture as much of CaaMTech’s scientific innovation as possible in our intellectual property portfolio as we develop the next generation of psychedelic.” drugs.”

“The approval of our first patent application has given a boost of energy to the team that has worked diligently over the past four years to bring it to the finish line,” Chadeayne said in the announcement. “With hundreds of applications still to be processed, this is a great start.”

“Strong patent protection and basic research give our drugs the essential support they need to progress through clinical trials and become FDA-approved drugs,” he added. “’Compositions and Methods Involving a Psilocybin Derivative’ covers (among other topics) the synergistic modulating effects of cannabinoids on the activation of serotonin receptors when administered in conjunction with a serotonin agonist.” In simple terms, CaaMTech has shown that cannabinoids act synergistically with psychedelic tryptamines and exert their effects. In doing so, CaaMTech has demonstrated the potential of two drugs, once classified by the U.S. federal government as having “no known medical value,” to treat some of the world’s most challenging mental health problems.”

The announcement said: “Notice about the allowance [from the the US Patent and Trademark Office (USPTO)] is a turning point for CaaMTech’s intellectual property division, which has filed over a hundred additional patent applications since filing the application in 2017.”

“Approval is the final scrutiny hurdle before a patent is granted,” the announcement reads.

Since the approval of this patent in 2021, Greenstate reports that “Among other things, CaaMTech has shared findings related to 4-PrO-DMT as a novel synthetic alternative to psilocybin.”

“Discrete efforts can complement this work, like SABI Mind’s research survey, which covers a myriad of topics, such as popular acceptance or disregard for synthetic alternatives to compounds like psilocybin. These moves, along with the policy work, create broader avenues of access for patients seeking trusted, science-based psychedelic therapies,” the outlet reported.

The development of the connection will not be easy. As MJBizDaily explained, there are “significant barriers to creating a combination connection.”

“Cannabinoids and psychedelics act on different receptors in the brain. Cannabinoids like THC primarily bind to the CB1 cannabinoid receptor; CBC mainly binds to the CB2 receptor. Psychedelics like psilocybin primarily bind to 5-HT2A serotonin receptors,” the outlet reported.

“But there is research showing that the cannabinoid CBD can bind to serotonin and that when serotonin is linked to a CB2 cannabinoid receptor, the resulting combination can do things that neither receptor can do alone… Aided by the potential.” des.” Combo Compound is gaining popularity in the medical cannabis community. For example, cannabis combined with psychedelics has been found to significantly shrink breast cancer tumors.”

Based in Issaquah, Washington, CaaMTech bills itself as “the leading drug discovery and lead optimization company focused on the development of psychedelic drugs that meet the standards of modern medicine.”